ART Advanced Research Technologies to Present at the BioContact Quebec Investor Conference

  ART Advanced Research Technologies Inc. ("ART") (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announced today that Mr. Sebastien Gignac, ART's Chairman and Chief Executive Officer, will present a company overview at the BioContact investor conference being held at the Fairmount Chateau Frontenac in Quebec City (Canada) from October 1 to 3. Mr. Gignac's presentation will take place on Wednesday, October 1st, 2008, at 3 p.m. (EST) in the Place d'Armes Room.

BioContact is a leading biopharmaceutical partnership symposium, gathering over 1000 participants from North America and Europe.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. Finally, the Fenestra® line of molecular imaging contrast products provides image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. ART is commercializing some of these products in a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at www.art.ca.

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in ART's most recent Annual Information Form and the financial statements for the year ended December 31, 2007, available on SEDAR (www.sedar.com).

Contacts: ART Advanced Research Technologies Inc. Chief Financial Officer Jacques Bedard [e-mail] www.art.ca